Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Reshetnykova, T
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Sandhya, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Overbeek, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Valdes, M Florenzano
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Reyes, C
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Gonzalez, F Saavedra
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Rozas, R Maturana
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25